Capital Wealth Planning LLC lowered its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 30.8% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 803,685 shares of the company’s stock after selling 356,962 shares during the period. Johnson & Johnson makes up 3.0% of Capital Wealth Planning LLC’s investment portfolio, making the stock its 19th largest position. Capital Wealth Planning LLC’s holdings in Johnson & Johnson were worth $137,487,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of JNJ. US Asset Management LLC acquired a new stake in shares of Johnson & Johnson in the third quarter worth $30,000. Steward Financial Group LLC acquired a new stake in Johnson & Johnson during the fourth quarter valued at $34,000. Jackson Wealth Management LLC grew its position in Johnson & Johnson by 1.7% during the third quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company’s stock valued at $40,000 after buying an additional 277 shares during the period. Iron Horse Wealth Management LLC lifted its holdings in Johnson & Johnson by 29.9% during the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock valued at $45,000 after purchasing an additional 61 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its holdings in Johnson & Johnson by 290.7% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company’s stock valued at $47,000 after purchasing an additional 218 shares in the last quarter. 67.84% of the stock is owned by institutional investors and hedge funds.
Shares of JNJ stock opened at $180.10 on Tuesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.35 and a quick ratio of 1.12. The firm’s 50-day moving average is $172.50 and its two-hundred day moving average is $168.01. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $184.20. The company has a market capitalization of $473.53 billion, a PE ratio of 22.75, a price-to-earnings-growth ratio of 2.71 and a beta of 0.72.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th will be given a dividend of $1.13 per share. The ex-dividend date of this dividend is Monday, May 23rd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.51%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 54.29%.
Several equities analysts have issued reports on JNJ shares. StockNews.com started coverage on shares of Johnson & Johnson in a report on Thursday, March 31st. They set a “strong-buy” rating on the stock. The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 6th. Raymond James raised their price target on shares of Johnson & Johnson from $185.00 to $195.00 and gave the stock an “outperform” rating in a research note on Thursday, April 14th. Finally, Bank of America assumed coverage on shares of Johnson & Johnson in a research note on Wednesday, March 2nd. They issued a “neutral” rating on the stock. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $184.57.
In other Johnson & Johnson news, VP Thibaut Mongon sold 23,681 shares of Johnson & Johnson stock in a transaction dated Thursday, March 17th. The shares were sold at an average price of $176.25, for a total transaction of $4,173,776.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.35% of the stock is owned by company insiders.
Johnson & Johnson Profile (Get Rating)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Fastenal Stock is Ready to Sprint Higher
- J.B. Hunt Transportation Services Fires On All Cylinders
- 3 No-Brainer Stocks to Buy with $1000
- Rite Aid Stock is Getting Cheap Enough to Buy Here
- Analysts Reel In Netflix Targets Ahead Of Q1 Earnings
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.